Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges

被引：18
|
作者：
Koutras, A. K. [1 ]
Starakis, I. [1 ]
Kyriakopoulou, U. [1 ]
Katsaounis, P. [1 ]
Nikolakopoulos, A. [1 ]
Kalofonos, H. P. [1 ]
机构：
[1] Univ Hosp Patras, Div Oncol, Dept Med, Rion, Greece
来源：
CURRENT MEDICINAL CHEMISTRY | 2011年 / 18卷 / 11期
关键词：
Bevacizumab; cetuximab; colorectal cancer; panitumumab; targeted therapy; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; CETUXIMAB PLUS IRINOTECAN; MONOCLONAL-ANTIBODY; KRAS MUTATIONS; 1ST-LINE TREATMENT; TUMOR-GROWTH; PANITUMUMAB MONOTHERAPY; IONIZING-RADIATION; INDUCED ACTIVATION;
D O I：
10.2174/092986711795471338
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last years, particularly with the introduction of targeted therapies. Two groups of agents targeting either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) have been integrated into clinical practice. Currently available agents with established role include the anti-EGFR monoclonal antibodies (mAbs) cetuximab/panitumumab and the anti-VEGF mAb bevacizumab. This review presents an update on the clinical studies evaluating the role of anti-EGFR and anti-VEGF agents in mCRC. Moreover, we provide current data regarding the mechanism of action and pathways mediating resistance to these agents. In addition, we present recent data with respect to biomarkers and we discuss future therapeutic strategies.
引用
收藏
页码：1599 / 1612
页数：14
相关论文
共 50 条
  • [21] Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions
    Zhang, Huici
    Zhang, Xiaoyu
    Ma, Xijun
    Wang, Xuan
    PHARMACOLOGICAL REPORTS, 2025, 77 (01) : 72 - 86
  • [22] HCV-targeted Antivirals: Current Status and Future Challenges
    Gemma, Sandra
    Brogi, Simone
    Novellino, Ettore
    Campiani, Giuseppe
    Maga, Giovanni
    Brindisi, Margherita
    Butini, Stefania
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (21) : 3445 - 3464
  • [23] HER2 targeted therapy in colorectal Cancer: Current landscape and future directions
    Chen, Na
    He, Ling
    Zou, Qiang
    Deng, Hongxin
    BIOCHEMICAL PHARMACOLOGY, 2024, 223
  • [24] Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
    Jacobsen, Anne
    Siebler, Juergen
    Gruetzmann, Robert
    Stuerzl, Michael
    Naschberger, Elisabeth
    CANCERS, 2024, 16 (05)
  • [25] Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions
    Johnson, David
    Chee, Cheng Ean
    Wong, Wesley
    Lam, Rachel C. T.
    Tan, Iain Bee Huat
    Ma, Brigette B. Y.
    CANCER TREATMENT REVIEWS, 2024, 125
  • [26] Computer vision in colorectal surgery: Current status and future challenges
    Kitaguchi, Daichi
    Ito, Masaaki
    SEMINARS IN COLON AND RECTAL SURGERY, 2024, 35 (01)
  • [27] Bacteriophage therapy in aquaculture: current status and future challenges
    Ruyin Liu
    Ganghua Han
    Zong Li
    Shujuan Cun
    Bin Hao
    Jianping Zhang
    Xinchun Liu
    Folia Microbiologica, 2022, 67 : 573 - 590
  • [28] Bacteriophage therapy in aquaculture: current status and future challenges
    Liu, Ruyin
    Han, Ganghua
    Li, Zong
    Cun, Shujuan
    Hao, Bin
    Zhang, Jianping
    Liu, Xinchun
    FOLIA MICROBIOLOGICA, 2022, 67 (04) : 573 - 590
  • [29] Re: Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges
    Siegel, Cary
    JOURNAL OF UROLOGY, 2018, 199 (04): : 873 - 873
  • [30] PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects
    Parghane, Rahul, V
    Basu, Sandip
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (09) : 959 - 975
12345